TRUMENBA® Clinical Studies

(Meningococcal Group B Vaccine)

14 CLINICAL STUDIES

The immunogenicity of Trumenba described in this section is based on results from four clinical studies:

•
Following the two-dose schedule (0 and 6 months) in subjects 10 through 25 years of age in the U.S. and Europe (Study 1057);
•
Following the three-dose schedule (0, 2, and 6 months) in subjects 10 through 25 years of age in the U.S., Canada, and Europe (Studies 1009 and 1016); and
•
Following the two-dose (0 and 6 months) and three-dose schedules (0, 1–2, and 6 months) in subjects 11 through 18 years of age in Europe (Study 1012).

Serum bactericidal antibodies were measured with hSBA assays that used each of four meningococcal serogroup B strains. These four primary test strains express fHbp variants representing the two subfamilies (A and B) of meningococcal serogroup B strains causing invasive disease in the U.S. and Europe. The studies assessed the proportions of subjects with a 4-fold or greater increase in hSBA titer for each of the four primary strains. The studies also assessed the composite response to the four primary strains combined (proportion of subjects who achieved a hSBA titer greater than or equal to 1:8 [three strains] and 1:16 [one strain]). To assess the effectiveness of the two- and three-dose schedules of Trumenba against diverse meningococcal serogroup B strains, the proportion of subjects achieving a defined hSBA titer (≥LLOQ) following completion of the two- or three-dose series was evaluated against a panel of 10 additional strains, each expressing a different fHbp variant.

14.1 Immunogenicity

The hSBA responses to each of the primary strains observed after the second dose of Trumenba in Study 1057 are presented in Table 7.

Table 7: Percentages of Subjects 10 through 25 Years of Age With ≥4-fold Rise in hSBA Titer and Composite Response Following Administration of Trumenba on a 0-and 6-Month Schedule for Four Primary Strains (Study 1057)*,†
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation; LOD=limit of detection.
Note: LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44.
Note: The 4-fold increase is defined as follows: (1) For subjects with a baseline hSBA titer <1:4, a response is defined as an hSBA titer ≥1:16. (2) For subjects with a baseline hSBA titer ≥ LOD and < LLOQ, a response is defined as an hSBA titer ≥4 times the LLOQ. (3) For subjects with a baseline hSBA titer ≥ LLOQ, a response is defined as an hSBA titer ≥4 times the baseline titer.
Note: Pre-specified criteria for assessment of hSBA responses (4-fold rise in titer to each primary test strain, and titer above LLOQ for all four primary test strains) among subjects in the U.S. and Europe were met in this study for all test strains except strain A22. Pre-specified criteria for the lower bound of the 95% CI for 4-fold rise in titer were set at 75%, 85%, 55%, and 60%, respectively, for A22, A56, B24, and B44, and 65% for the composite hSBA response for all four primary test strains.
*
Evaluable immunogenicity population.
†
Study 1057: NCT03135834.
‡
For the second dose, serum was obtained approximately 1 month after vaccination.
§
For ≥4-fold increase, N=number of subjects with valid and determinate hSBA titers for the given strain at both the specified time point and baseline. For composite hSBA response, N=number of subjects with valid and determinate hSBA results on all 4 strains at the given time point. U.S. subjects constituted approximately 80% of the total subjects evaluated for immunogenicity.
Exact 2-sided confidence interval (Clopper-Pearson method) based upon the observed proportion of subjects.
#
Composite response = hSBA ≥ LLOQ for all 4 primary meningococcal B strains.

fHbp Variant‡

N§

%
(95% CI)

≥4-Fold Increase

PMB80 (A22)

     Dose 2

827

73.8
(70.6, 76.7)

PMB2001 (A56)

     Dose 2

823

95.0
(93.3, 96.4)

PMB2948 (B24)

     Dose 2

835

67.4
(64.1, 70.6)

PMB2707 (B44)

     Dose 2

850

86.4
(83.9, 88.6)

Composite hSBA Response#

     Before Dose 1

799

1.8
(1.0, 2.9)

     Dose 2

814

74.3
(71.2, 77.3)

The hSBA responses after the second dose of Trumenba in Study 1057 against a panel of 10 additional strains representing the diversity of meningococcal fHbp types prevalent among strains circulating in the US are presented in Table 8.

Table 8. Percentages of Subjects 10 through 25 Years of Age With a hSBA Titer ≥ LLOQ Against 10 Additional Strains Following Administration of Trumenba on a 0- and 6-Month Schedule (Study 1057)*,†
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation.
Note: LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16.
*
The evaluable immunogenicity population was used for the analysis.
†
Study 1057: NCT03135834.
‡
For the second dose, serum was obtained approximately 1 month after vaccination.
§
N=number of subjects with valid and determinate hSBA titers for the given strain. U.S. subjects constituted approximately 80% of the total subjects evaluated for immunogenicity.
Exact 2-sided confidence interval (Clopper and Pearson) based upon the observed proportion of subjects.

fHbp Variant‡

N§

%
(95% CI)

PMB3175 (A29)

     Before Dose 1

166

4.8
(2.1, 9.3)

     Dose 2

166

95.2
(90.7, 97.9)

PMB3010 (A06)

     Before Dose 1

157

5.7
(2.7, 10.6)

     Dose 2

159

89.3
(83.4, 93.6)

PMB3040 (A07)

     Before Dose 1

150

32.0
(24.6, 40.1)

     Dose 2

157

96.8
(92.7, 99.0)

PMB824 (A12)

     Before Dose 1

154

5.2
(2.3, 10.0)

     Dose 2

157

83.4
(76.7, 88.9)

PMB1672 (A15)

     Before Dose 1

166

22.9
(16.7, 30.0)

     Dose 2

165

89.1
(83.3, 93.4)

PMB1989 (A19)

     Before Dose 1

167

5.4
(2.5, 10.0)

     Dose 2

167

90.4
(84.9, 94.4)

PMB1256 (B03)

     Before Dose 1

172

3.5
(1.3, 7.4)

     Dose 2

164

74.4
(67.0, 80.9)

PMB866 (B09)

     Before Dose 1

171

9.9
(5.9, 15.4)

     Dose 2

166

71.1
(63.6, 77.8)

PMB431 (B15)

     Before Dose 1

172

6.4
(3.2, 11.2)

     Dose 2

167

85.0
(78.7, 90.1)

PMB648 (B16)

     Before Dose 1

172

8.1
(4.5, 13.3)

     Dose 2

164

77.4
(70.3, 83.6)

The hSBA responses to each of the primary strains observed in U.S. subjects after the third dose of Trumenba are presented for Study 1009 and Study 1016 in Table 9.

Table 9: Percentages of U.S. Subjects 10 through 25 Years of Age With ≥4-fold Rise in hSBA Titer and Composite Response Following Administration of Trumenba on a 0-, 2-, and 6-Month Schedule for Four Primary Strains (Studies 1009 and 1016)*,†,‡,§
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation; LOD=limit of detection.
Note: LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44.
Note: The 4-fold increase is defined as follows: (1) For subjects with a baseline hSBA titer <1:4, a response is defined as an hSBA titer ≥1:16. (2) For subjects with a baseline hSBA titer ≥ LOD and < LLOQ, a response is defined as an hSBA titer ≥4 times the LLOQ. (3) For subjects with a baseline hSBA titer ≥ LLOQ, a response is defined as an hSBA titer ≥4 times the baseline titer.
Note: Pre-specified criteria for assessment of hSBA responses (4-fold rise in titer to each primary test strain, and titer above LLOQ for all four primary test strains) among U.S. subjects were met in these studies. For Study 1009 pre-specified criteria for the lower bound of the 95% CI for 4-fold rise in titer were set at 75%, 85%, 65%, and 60%, respectively, for A22, A56, B24 and B44, and 75% for the composite hSBA response for all four primary test strains. For Study 1016 pre-specified criteria for the lower bound of the 95% CI for 4-fold rise in titer were set at 55%, 85%, 50%, and 60%, respectively, for A22, A56, B24, and B44, and 60% for the composite hSBA response for all four primary test strains.
*
Evaluable immunogenicity population.
†
Study 1009: NCT01830855, and Study 1016: NCT01352845.
‡
Study 1009: Group 1 (0, 2, and 6 months).
§
Study 1016: Group 1 (0, 2, and 6 months).
For ≥4-fold increase, N=number of subjects with valid and determinate hSBA titers for the given strain at both the specified time point and baseline. For composite hSBA response, N=number of subjects with valid and determinate hSBA results on all 4 strains at the given time point.
#
Exact 2-sided confidence interval (Clopper-Pearson method) based upon the observed proportion of subjects.
Þ
For the third dose, serum was obtained approximately 1 month after vaccination.
ß
Composite response = hSBA ≥ LLOQ for all 4 primary meningococcal B strains.

Study 1009

Study 1016

(10 through 18 Years of Age)

(18 through 25 Years of Age)

N

%
(95% CI)#

N

%
(95% CI)#

fHbp VariantÞ

≥4-Fold Increase

PMB80 (A22)

     Dose 3

587

86.2
(83.1, 88.9)

644

81.1
(77.8, 84.0)

PMB2001 (A56)

     Dose 3

526

92.0
(89.4, 94.2)

621

90.7
(88.1, 92.8)

PMB2948 (B24)

     Dose 3

585

81.9
(78.5, 84.9)

634

83.9
(80.8, 86.7)

PMB2707 (B44)

     Dose 3

555

88.3
(85.3, 90.8)

643

79.3
(76.0, 82.4)

Composite hSBA Responseß

     Before Dose 1

507

0.6
(0.1, 1.7)

610

3.3
(2.0, 5.0)

     Dose 3

537

85.7
(82.4, 88.5)

625

82.4
(79.2, 85.3)

The hSBA responses after the third dose of Trumenba against a panel of 10 additional strains representing the diversity of meningococcal fHbp types prevalent among strains circulating in the U.S. are presented for Study 1009, and Study 1016 in Table10.

Table 10. Percentages of U.S. Subjects 10 through 25 Years of Age With a hSBA Titer ≥ LLOQ Against 10 Additional Strains Following Administration of Trumenba on a 0-, 2-, and 6-Month Schedule (Study 1009 and Study 1016)*,†
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation.
Note: LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16.
*
The evaluable immunogenicity population was used for the analysis.
†
Study 1009: NCT01830855 and Study 1016 NCT01352845.
‡
For the third dose, serum was obtained approximately 1 month after vaccination.
§
N=number of subjects with valid and determinate hSBA titers for the given strain.
Exact 2-sided confidence interval (Clopper and Pearson) based upon the observed proportion of subjects.

     fHbp Variant‡

Study 1009

Study 1016

(10 through 18 Years of Age)

(18 through 25 Years of Age)

N§

%
(95% CI)

N§

%
(95% CI)

PMB3175 (A29)

     Before Dose 1

169

11.2
(6.9, 17.0)

160

23.8
(17.4, 31.1)

     Dose 3

176

98.9
(96.0, 99.9)

162

98.8
(95.6, 99.9)

PMB3010 (A06)

     Before Dose 1

178

7.9
(4.4, 12.8)

166

10.8
(6.6, 16.6)

     Dose 3

179

97.8
(94.4, 99.4)

164

89.0
(83.2, 93.4)

PMB3040 (A07)

     Before Dose 1

170

37.6
(30.3, 45.4)

165

55.8
(47.8, 63.5)

     Dose 3

178

96.1
(92.1, 98.4)

165

95.2
(90.7, 97.9)

PMB824 (A12)

     Before Dose 1

180

5.0
(2.3, 9.3)

166

4.8
(2.1, 9.3)

     Dose 3

180

76.1
(69.2, 82.1)

165

66.7
(58.9, 73.8)

PMB1672 (A15)

     Before Dose 1

170

15.9
(10.7, 22.3)

159

30.2
(23.2, 38.0)

     Dose 3

166

86.7
(80.6, 91.5)

159

89.9
(84.2, 94.1)

PMB1989 (A19)

     Before Dose 1

174

5.7
(2.8, 10.3)

158

23.4
(17.1, 30.8)

     Dose 3

173

91.9
(86.8, 95.5)

163

94.5
(89.8, 97.4)

PMB1256 (B03)

     Before Dose 1

183

2.2
(0.6, 5.5)

164

5.5
(2.5, 10.2)

     Dose 3

181

92.3
(87.4, 95.7)

161

84.5
(77.9, 89.7)

PMB866 (B09)

     Before Dose 1

180

12.2
(7.8, 17.9)

165

13.9
(9.0, 20.2)

     Dose 3

182

85.7
(79.8, 90.5)

162

72.2
(64.7, 79.0)

PMB431 (B15)

     Before Dose 1

180

27.8
(21.4, 34.9)

163

33.1
(26.0, 40.9)

     Dose 3

183

97.3
(93.7, 99.1)

163

95.7
(91.4, 98.3)

PMB648 (B16)

     Before Dose 1

180

6.7
(3.5, 11.4)

161

11.8
(7.3, 17.8)

     Dose 3

180

83.9
(77.7, 88.9)

159

72.3
(64.7, 79.1)

In Study 1012, Trumenba was administered according to different schedules, including Group 1 (0, 1, and 6 months), Group 2 (0, 2, and 6 months) and Group 3 (0 and 6 months). The hSBA responses observed after the second dose in Groups 1, 2, and 3 and completion of the three-dose series in Group 1 and 2 are presented in Table 11.

Table 11: Percentages of European Subjects 11 through 18 Years of Age With a ≥4-Fold Increase in hSBA Titer and Composite Response*,† (Study 1012)
Group 1Group 2Group 3
3-Dose Schedule
(0, 1, and 6 Months)‡		3-Dose Schedule
(0, 2, and 6 Months)§		2-Dose Schedule
(0 and 6 Months)
fHbp Variant#%
(95% CI)Þ		%
(95% CI)Þ		%
(95% CI)Þ
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation; NA=not applicable.
Note: LLOQ = 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
Note: The ≥4-fold increase is defined as follows: (1) For subjects with a baseline hSBA titer <1:4, a ≥4-fold increase was defined as an hSBA titer ≥1:16. (2) For subjects with a baseline hSBA titer ≥ LOD and < LLOQ, a response is defined as an hSBA titer ≥4 times the LLOQ. (3) For subjects with a baseline hSBA titer ≥ LLOQ, a response is defined as an hSBA titer ≥4 times the baseline titer.
*
Per-schedule Evaluable populations. Dose 2 data include subjects who received two doses, irrespective of whether they received the third dose.
†
Study1012: NCT01299480.
‡
Group 1 (0, 1, and 6 months). The denominators ranged from 173 to 187 after Dose 2 and 178 to 188 after Dose 3, depending on the strain.
§
Group 2 (0, 2, and 6 months). The denominators ranged from 229 to 240 after Dose 2 and 159 to 162 after Dose 3, depending on the strain.
Group 3 (0 and 6 months). The denominators ranged from 188 to 203 after Dose 2, depending on the strain.
#
For the second and third doses, serum was obtained approximately 1 month after vaccination.
Þ
Exact 2-sided confidence interval (Clopper and Pearson) based upon the observed proportion of subjects.
ß
Composite response = hSBA ≥LLOQ for all 4 primary meningococcal B strains.

≥4-Fold Increase

PMB80 (A22)

  Dose 2

58.8
(51.4, 66.0)

72.5
(66.4, 78.0)

82.3
(76.3, 87.3)

  Dose 3

77.6
(70.9, 83.4)

87.7
(81.6, 92.3)

NA

PMB2001 (A56)

  Dose 2

87.8
(82.2, 92.2)

90.7
(86.2, 94.1)

90.1
(85.1, 93.8)

  Dose 3

91.2
(86.1, 94.9)

93.8
(88.8, 97.0)

NA

PMB2948 (B24)

  Dose 2

51.1
(43.6, 58.5)

54.2
(47.7, 60.7)

64.5
(57.4, 71.1)

  Dose 3

74.1
(67.1, 80.2)

78.3
(71.1, 84.4)

NA

PMB2707 (B44)

  Dose 2

48.1
(40.7, 55.6)

53.4
(46.8, 59.9)

66.0
(58.9, 72.6)

  Dose 3

80.9
(74.5, 86.2)

78.6
(71.4, 84.7)

NA

Composite Responseß

  Before Dose 1

4.6
(2.0, 8.8)

2.2
(0.7, 5.0)

1.5
(0.3, 4.4)

  Dose 2

52.0
(44.3, 59.7)

52.0
(45.3, 58.6)

72.9
(65.9, 79.1)

  Dose 3

80.3
(73.7, 85.9)

81.8
(74.9, 87.4)

NA

14.2 Concomitant Vaccine Administration

Study B1971011 (Study 1011) evaluated the immunogenicity of concomitantly administered Trumenba and Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant (HPV4) (Merck & Co, Inc.). U.S. subjects 11 through 17 years of age were randomized into three groups: Group 1 received Trumenba and HPV4 (N=992), Group 2 received Trumenba and saline (N=990), and Group 3 received saline and HPV4 (N=501). All vaccines were administered according to a 0-, 2- and 6-month schedule. Immune responses were evaluated by comparisons of geometric mean titer [GMT] for each HPV type at 1 month after the third HPV4 vaccination (Group 1 vs. Group 3), and hSBA GMTs using two meningococcal serogroup B strains [variants A22 and B24] 1 month after the third Trumenba vaccination (Group 1 vs. Group 2). The noninferiority criteria for the comparisons of GMTs [lower limit of the 2-sided 95% confidence interval (CI) of the GMT ratio (Group 1/Group 3 for HPV and Group 1/Group 2 for meningococcal serogroup B strains) >0.67] were met for three HPV types (6, 11 and 16) and for the meningococcal serogroup B strains tested. For HPV-18, the lower bound of the 95% CI for the GMT ratio was 0.62 at 1 month after the third HPV4 vaccination

Study B1971015 (Study 1015) evaluated the immunogenicity of concomitantly administered Trumenba and Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MenACWY) (Sanofi Pasteur Inc.) and Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) (Sanofi Pasteur Ltd.) vaccines. U.S. subjects 10 through 12 years of age were randomized into three groups: Group 1 received Trumenba at 0, 2, and 6 months, and MenACWY and Tdap were coadministered with the first Trumenba dose (N=883). Group 2 received saline at 0, 2 and 6 months, and MenACWY and Tdap were coadministered with the first saline injection (N=870). Group 3 received Trumenba at 0, 2 and 6 months, and saline was coadministered with the first Trumenba dose (N=875). Immune responses were evaluated by comparisons of GMTs for each of the MenACWY and Tdap antigens 1 month after the first Trumenba vaccination, and hSBA GMTs using two meningococcal serogroup B strains [variants A22 and B24] 1 month after the third Trumenba vaccination. The noninferiority criteria for the comparisons of GMTs [lower limit of the 2-sided 95% CI of the GMT ratio (Group 1/Group 3 for meningococcal serogroup B strains and Group 1/Group 2 for MenACWY and Tdap) >0.67] were met for all antigens.

Find TRUMENBA® medical information:

Find TRUMENBA® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TRUMENBA® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Clinical Studies

14 CLINICAL STUDIES

The immunogenicity of Trumenba described in this section is based on results from four clinical studies:

•
Following the two-dose schedule (0 and 6 months) in subjects 10 through 25 years of age in the U.S. and Europe (Study 1057);
•
Following the three-dose schedule (0, 2, and 6 months) in subjects 10 through 25 years of age in the U.S., Canada, and Europe (Studies 1009 and 1016); and
•
Following the two-dose (0 and 6 months) and three-dose schedules (0, 1–2, and 6 months) in subjects 11 through 18 years of age in Europe (Study 1012).

Serum bactericidal antibodies were measured with hSBA assays that used each of four meningococcal serogroup B strains. These four primary test strains express fHbp variants representing the two subfamilies (A and B) of meningococcal serogroup B strains causing invasive disease in the U.S. and Europe. The studies assessed the proportions of subjects with a 4-fold or greater increase in hSBA titer for each of the four primary strains. The studies also assessed the composite response to the four primary strains combined (proportion of subjects who achieved a hSBA titer greater than or equal to 1:8 [three strains] and 1:16 [one strain]). To assess the effectiveness of the two- and three-dose schedules of Trumenba against diverse meningococcal serogroup B strains, the proportion of subjects achieving a defined hSBA titer (≥LLOQ) following completion of the two- or three-dose series was evaluated against a panel of 10 additional strains, each expressing a different fHbp variant.

14.1 Immunogenicity

The hSBA responses to each of the primary strains observed after the second dose of Trumenba in Study 1057 are presented in Table 7.

Table 7: Percentages of Subjects 10 through 25 Years of Age With ≥4-fold Rise in hSBA Titer and Composite Response Following Administration of Trumenba on a 0-and 6-Month Schedule for Four Primary Strains (Study 1057)*,†
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation; LOD=limit of detection.
Note: LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44.
Note: The 4-fold increase is defined as follows: (1) For subjects with a baseline hSBA titer <1:4, a response is defined as an hSBA titer ≥1:16. (2) For subjects with a baseline hSBA titer ≥ LOD and < LLOQ, a response is defined as an hSBA titer ≥4 times the LLOQ. (3) For subjects with a baseline hSBA titer ≥ LLOQ, a response is defined as an hSBA titer ≥4 times the baseline titer.
Note: Pre-specified criteria for assessment of hSBA responses (4-fold rise in titer to each primary test strain, and titer above LLOQ for all four primary test strains) among subjects in the U.S. and Europe were met in this study for all test strains except strain A22. Pre-specified criteria for the lower bound of the 95% CI for 4-fold rise in titer were set at 75%, 85%, 55%, and 60%, respectively, for A22, A56, B24, and B44, and 65% for the composite hSBA response for all four primary test strains.
*
Evaluable immunogenicity population.
†
Study 1057: NCT03135834.
‡
For the second dose, serum was obtained approximately 1 month after vaccination.
§
For ≥4-fold increase, N=number of subjects with valid and determinate hSBA titers for the given strain at both the specified time point and baseline. For composite hSBA response, N=number of subjects with valid and determinate hSBA results on all 4 strains at the given time point. U.S. subjects constituted approximately 80% of the total subjects evaluated for immunogenicity.
Exact 2-sided confidence interval (Clopper-Pearson method) based upon the observed proportion of subjects.
#
Composite response = hSBA ≥ LLOQ for all 4 primary meningococcal B strains.

fHbp Variant‡

N§

%
(95% CI)

≥4-Fold Increase

PMB80 (A22)

     Dose 2

827

73.8
(70.6, 76.7)

PMB2001 (A56)

     Dose 2

823

95.0
(93.3, 96.4)

PMB2948 (B24)

     Dose 2

835

67.4
(64.1, 70.6)

PMB2707 (B44)

     Dose 2

850

86.4
(83.9, 88.6)

Composite hSBA Response#

     Before Dose 1

799

1.8
(1.0, 2.9)

     Dose 2

814

74.3
(71.2, 77.3)

The hSBA responses after the second dose of Trumenba in Study 1057 against a panel of 10 additional strains representing the diversity of meningococcal fHbp types prevalent among strains circulating in the US are presented in Table 8.

Table 8. Percentages of Subjects 10 through 25 Years of Age With a hSBA Titer ≥ LLOQ Against 10 Additional Strains Following Administration of Trumenba on a 0- and 6-Month Schedule (Study 1057)*,†
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation.
Note: LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16.
*
The evaluable immunogenicity population was used for the analysis.
†
Study 1057: NCT03135834.
‡
For the second dose, serum was obtained approximately 1 month after vaccination.
§
N=number of subjects with valid and determinate hSBA titers for the given strain. U.S. subjects constituted approximately 80% of the total subjects evaluated for immunogenicity.
Exact 2-sided confidence interval (Clopper and Pearson) based upon the observed proportion of subjects.

fHbp Variant‡

N§

%
(95% CI)

PMB3175 (A29)

     Before Dose 1

166

4.8
(2.1, 9.3)

     Dose 2

166

95.2
(90.7, 97.9)

PMB3010 (A06)

     Before Dose 1

157

5.7
(2.7, 10.6)

     Dose 2

159

89.3
(83.4, 93.6)

PMB3040 (A07)

     Before Dose 1

150

32.0
(24.6, 40.1)

     Dose 2

157

96.8
(92.7, 99.0)

PMB824 (A12)

     Before Dose 1

154

5.2
(2.3, 10.0)

     Dose 2

157

83.4
(76.7, 88.9)

PMB1672 (A15)

     Before Dose 1

166

22.9
(16.7, 30.0)

     Dose 2

165

89.1
(83.3, 93.4)

PMB1989 (A19)

     Before Dose 1

167

5.4
(2.5, 10.0)

     Dose 2

167

90.4
(84.9, 94.4)

PMB1256 (B03)

     Before Dose 1

172

3.5
(1.3, 7.4)

     Dose 2

164

74.4
(67.0, 80.9)

PMB866 (B09)

     Before Dose 1

171

9.9
(5.9, 15.4)

     Dose 2

166

71.1
(63.6, 77.8)

PMB431 (B15)

     Before Dose 1

172

6.4
(3.2, 11.2)

     Dose 2

167

85.0
(78.7, 90.1)

PMB648 (B16)

     Before Dose 1

172

8.1
(4.5, 13.3)

     Dose 2

164

77.4
(70.3, 83.6)

The hSBA responses to each of the primary strains observed in U.S. subjects after the third dose of Trumenba are presented for Study 1009 and Study 1016 in Table 9.

Table 9: Percentages of U.S. Subjects 10 through 25 Years of Age With ≥4-fold Rise in hSBA Titer and Composite Response Following Administration of Trumenba on a 0-, 2-, and 6-Month Schedule for Four Primary Strains (Studies 1009 and 1016)*,†,‡,§
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation; LOD=limit of detection.
Note: LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44.
Note: The 4-fold increase is defined as follows: (1) For subjects with a baseline hSBA titer <1:4, a response is defined as an hSBA titer ≥1:16. (2) For subjects with a baseline hSBA titer ≥ LOD and < LLOQ, a response is defined as an hSBA titer ≥4 times the LLOQ. (3) For subjects with a baseline hSBA titer ≥ LLOQ, a response is defined as an hSBA titer ≥4 times the baseline titer.
Note: Pre-specified criteria for assessment of hSBA responses (4-fold rise in titer to each primary test strain, and titer above LLOQ for all four primary test strains) among U.S. subjects were met in these studies. For Study 1009 pre-specified criteria for the lower bound of the 95% CI for 4-fold rise in titer were set at 75%, 85%, 65%, and 60%, respectively, for A22, A56, B24 and B44, and 75% for the composite hSBA response for all four primary test strains. For Study 1016 pre-specified criteria for the lower bound of the 95% CI for 4-fold rise in titer were set at 55%, 85%, 50%, and 60%, respectively, for A22, A56, B24, and B44, and 60% for the composite hSBA response for all four primary test strains.
*
Evaluable immunogenicity population.
†
Study 1009: NCT01830855, and Study 1016: NCT01352845.
‡
Study 1009: Group 1 (0, 2, and 6 months).
§
Study 1016: Group 1 (0, 2, and 6 months).
For ≥4-fold increase, N=number of subjects with valid and determinate hSBA titers for the given strain at both the specified time point and baseline. For composite hSBA response, N=number of subjects with valid and determinate hSBA results on all 4 strains at the given time point.
#
Exact 2-sided confidence interval (Clopper-Pearson method) based upon the observed proportion of subjects.
Þ
For the third dose, serum was obtained approximately 1 month after vaccination.
ß
Composite response = hSBA ≥ LLOQ for all 4 primary meningococcal B strains.

Study 1009

Study 1016

(10 through 18 Years of Age)

(18 through 25 Years of Age)

N

%
(95% CI)#

N

%
(95% CI)#

fHbp VariantÞ

≥4-Fold Increase

PMB80 (A22)

     Dose 3

587

86.2
(83.1, 88.9)

644

81.1
(77.8, 84.0)

PMB2001 (A56)

     Dose 3

526

92.0
(89.4, 94.2)

621

90.7
(88.1, 92.8)

PMB2948 (B24)

     Dose 3

585

81.9
(78.5, 84.9)

634

83.9
(80.8, 86.7)

PMB2707 (B44)

     Dose 3

555

88.3
(85.3, 90.8)

643

79.3
(76.0, 82.4)

Composite hSBA Responseß

     Before Dose 1

507

0.6
(0.1, 1.7)

610

3.3
(2.0, 5.0)

     Dose 3

537

85.7
(82.4, 88.5)

625

82.4
(79.2, 85.3)

The hSBA responses after the third dose of Trumenba against a panel of 10 additional strains representing the diversity of meningococcal fHbp types prevalent among strains circulating in the U.S. are presented for Study 1009, and Study 1016 in Table10.

Table 10. Percentages of U.S. Subjects 10 through 25 Years of Age With a hSBA Titer ≥ LLOQ Against 10 Additional Strains Following Administration of Trumenba on a 0-, 2-, and 6-Month Schedule (Study 1009 and Study 1016)*,†
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation.
Note: LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16.
*
The evaluable immunogenicity population was used for the analysis.
†
Study 1009: NCT01830855 and Study 1016 NCT01352845.
‡
For the third dose, serum was obtained approximately 1 month after vaccination.
§
N=number of subjects with valid and determinate hSBA titers for the given strain.
Exact 2-sided confidence interval (Clopper and Pearson) based upon the observed proportion of subjects.

     fHbp Variant‡

Study 1009

Study 1016

(10 through 18 Years of Age)

(18 through 25 Years of Age)

N§

%
(95% CI)

N§

%
(95% CI)

PMB3175 (A29)

     Before Dose 1

169

11.2
(6.9, 17.0)

160

23.8
(17.4, 31.1)

     Dose 3

176

98.9
(96.0, 99.9)

162

98.8
(95.6, 99.9)

PMB3010 (A06)

     Before Dose 1

178

7.9
(4.4, 12.8)

166

10.8
(6.6, 16.6)

     Dose 3

179

97.8
(94.4, 99.4)

164

89.0
(83.2, 93.4)

PMB3040 (A07)

     Before Dose 1

170

37.6
(30.3, 45.4)

165

55.8
(47.8, 63.5)

     Dose 3

178

96.1
(92.1, 98.4)

165

95.2
(90.7, 97.9)

PMB824 (A12)

     Before Dose 1

180

5.0
(2.3, 9.3)

166

4.8
(2.1, 9.3)

     Dose 3

180

76.1
(69.2, 82.1)

165

66.7
(58.9, 73.8)

PMB1672 (A15)

     Before Dose 1

170

15.9
(10.7, 22.3)

159

30.2
(23.2, 38.0)

     Dose 3

166

86.7
(80.6, 91.5)

159

89.9
(84.2, 94.1)

PMB1989 (A19)

     Before Dose 1

174

5.7
(2.8, 10.3)

158

23.4
(17.1, 30.8)

     Dose 3

173

91.9
(86.8, 95.5)

163

94.5
(89.8, 97.4)

PMB1256 (B03)

     Before Dose 1

183

2.2
(0.6, 5.5)

164

5.5
(2.5, 10.2)

     Dose 3

181

92.3
(87.4, 95.7)

161

84.5
(77.9, 89.7)

PMB866 (B09)

     Before Dose 1

180

12.2
(7.8, 17.9)

165

13.9
(9.0, 20.2)

     Dose 3

182

85.7
(79.8, 90.5)

162

72.2
(64.7, 79.0)

PMB431 (B15)

     Before Dose 1

180

27.8
(21.4, 34.9)

163

33.1
(26.0, 40.9)

     Dose 3

183

97.3
(93.7, 99.1)

163

95.7
(91.4, 98.3)

PMB648 (B16)

     Before Dose 1

180

6.7
(3.5, 11.4)

161

11.8
(7.3, 17.8)

     Dose 3

180

83.9
(77.7, 88.9)

159

72.3
(64.7, 79.1)

In Study 1012, Trumenba was administered according to different schedules, including Group 1 (0, 1, and 6 months), Group 2 (0, 2, and 6 months) and Group 3 (0 and 6 months). The hSBA responses observed after the second dose in Groups 1, 2, and 3 and completion of the three-dose series in Group 1 and 2 are presented in Table 11.

Table 11: Percentages of European Subjects 11 through 18 Years of Age With a ≥4-Fold Increase in hSBA Titer and Composite Response*,† (Study 1012)
Group 1Group 2Group 3
3-Dose Schedule
(0, 1, and 6 Months)‡		3-Dose Schedule
(0, 2, and 6 Months)§		2-Dose Schedule
(0 and 6 Months)
fHbp Variant#%
(95% CI)Þ		%
(95% CI)Þ		%
(95% CI)Þ
Abbreviations: CI=confidence interval; fHbp=factor H binding protein; hSBA=serum bactericidal assay using human complement; LLOQ=lower limit of quantitation; NA=not applicable.
Note: LLOQ = 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
Note: The ≥4-fold increase is defined as follows: (1) For subjects with a baseline hSBA titer <1:4, a ≥4-fold increase was defined as an hSBA titer ≥1:16. (2) For subjects with a baseline hSBA titer ≥ LOD and < LLOQ, a response is defined as an hSBA titer ≥4 times the LLOQ. (3) For subjects with a baseline hSBA titer ≥ LLOQ, a response is defined as an hSBA titer ≥4 times the baseline titer.
*
Per-schedule Evaluable populations. Dose 2 data include subjects who received two doses, irrespective of whether they received the third dose.
†
Study1012: NCT01299480.
‡
Group 1 (0, 1, and 6 months). The denominators ranged from 173 to 187 after Dose 2 and 178 to 188 after Dose 3, depending on the strain.
§
Group 2 (0, 2, and 6 months). The denominators ranged from 229 to 240 after Dose 2 and 159 to 162 after Dose 3, depending on the strain.
Group 3 (0 and 6 months). The denominators ranged from 188 to 203 after Dose 2, depending on the strain.
#
For the second and third doses, serum was obtained approximately 1 month after vaccination.
Þ
Exact 2-sided confidence interval (Clopper and Pearson) based upon the observed proportion of subjects.
ß
Composite response = hSBA ≥LLOQ for all 4 primary meningococcal B strains.

≥4-Fold Increase

PMB80 (A22)

  Dose 2

58.8
(51.4, 66.0)

72.5
(66.4, 78.0)

82.3
(76.3, 87.3)

  Dose 3

77.6
(70.9, 83.4)

87.7
(81.6, 92.3)

NA

PMB2001 (A56)

  Dose 2

87.8
(82.2, 92.2)

90.7
(86.2, 94.1)

90.1
(85.1, 93.8)

  Dose 3

91.2
(86.1, 94.9)

93.8
(88.8, 97.0)

NA

PMB2948 (B24)

  Dose 2

51.1
(43.6, 58.5)

54.2
(47.7, 60.7)

64.5
(57.4, 71.1)

  Dose 3

74.1
(67.1, 80.2)

78.3
(71.1, 84.4)

NA

PMB2707 (B44)

  Dose 2

48.1
(40.7, 55.6)

53.4
(46.8, 59.9)

66.0
(58.9, 72.6)

  Dose 3

80.9
(74.5, 86.2)

78.6
(71.4, 84.7)

NA

Composite Responseß

  Before Dose 1

4.6
(2.0, 8.8)

2.2
(0.7, 5.0)

1.5
(0.3, 4.4)

  Dose 2

52.0
(44.3, 59.7)

52.0
(45.3, 58.6)

72.9
(65.9, 79.1)

  Dose 3

80.3
(73.7, 85.9)

81.8
(74.9, 87.4)

NA

14.2 Concomitant Vaccine Administration

Study B1971011 (Study 1011) evaluated the immunogenicity of concomitantly administered Trumenba and Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant (HPV4) (Merck & Co, Inc.). U.S. subjects 11 through 17 years of age were randomized into three groups: Group 1 received Trumenba and HPV4 (N=992), Group 2 received Trumenba and saline (N=990), and Group 3 received saline and HPV4 (N=501). All vaccines were administered according to a 0-, 2- and 6-month schedule. Immune responses were evaluated by comparisons of geometric mean titer [GMT] for each HPV type at 1 month after the third HPV4 vaccination (Group 1 vs. Group 3), and hSBA GMTs using two meningococcal serogroup B strains [variants A22 and B24] 1 month after the third Trumenba vaccination (Group 1 vs. Group 2). The noninferiority criteria for the comparisons of GMTs [lower limit of the 2-sided 95% confidence interval (CI) of the GMT ratio (Group 1/Group 3 for HPV and Group 1/Group 2 for meningococcal serogroup B strains) >0.67] were met for three HPV types (6, 11 and 16) and for the meningococcal serogroup B strains tested. For HPV-18, the lower bound of the 95% CI for the GMT ratio was 0.62 at 1 month after the third HPV4 vaccination

Study B1971015 (Study 1015) evaluated the immunogenicity of concomitantly administered Trumenba and Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MenACWY) (Sanofi Pasteur Inc.) and Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) (Sanofi Pasteur Ltd.) vaccines. U.S. subjects 10 through 12 years of age were randomized into three groups: Group 1 received Trumenba at 0, 2, and 6 months, and MenACWY and Tdap were coadministered with the first Trumenba dose (N=883). Group 2 received saline at 0, 2 and 6 months, and MenACWY and Tdap were coadministered with the first saline injection (N=870). Group 3 received Trumenba at 0, 2 and 6 months, and saline was coadministered with the first Trumenba dose (N=875). Immune responses were evaluated by comparisons of GMTs for each of the MenACWY and Tdap antigens 1 month after the first Trumenba vaccination, and hSBA GMTs using two meningococcal serogroup B strains [variants A22 and B24] 1 month after the third Trumenba vaccination. The noninferiority criteria for the comparisons of GMTs [lower limit of the 2-sided 95% CI of the GMT ratio (Group 1/Group 3 for meningococcal serogroup B strains and Group 1/Group 2 for MenACWY and Tdap) >0.67] were met for all antigens.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.